RAD50 and cancer: Analysis of the immunofluorescence data (Figures 4, 5 and 6) revealed that cells derived from hypersensitive cancer patients differed markedly in their Rad50 foci forming response to IR from the cells derived from healthy subjects and cells from cancer patients with normal clinical reaction to RT.